UPDATE: Raymond James Starts FibroGen (FGEN) at Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
FibroGen (FGEN) Steals the Show at ASN, Bodes Well for Upcoming PDUFA - Stifel
October 23, 2020 6:57 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating on FibroGen (NASDAQ: FGEN) after Roxadustat had an extensive presence at ASN Kidney Week. The highlight was the competitive profile and versatility of this new anemia-correcting agent (HIF-PHI) across multiple CKD patient types. The analyst... More
